Table 3.
Associations between the prevalence of AAA and the non-HDL-c/HDL-c ratio as continuous variables and in tertiles
| Variables | No. of participants (AAA patients) | Unadjusted OR (95%CI) | P value | Model 1a OR (95%CI) | P value | Model 2b OR (95%CI) | P value |
|---|---|---|---|---|---|---|---|
| non-HDL-c / HDL-c ratio | 9559 (219) | 1.391(1.269–1.526) | 0.001 | 1.417(1.287–1.56) | 0.001 | 1.584(1.411–1.778) | <0.001 |
| non-HDL-c / HDL-c ratio | |||||||
| <2.50 | 3187 (32) | 1.000 | 1.000 | 1.000 | |||
| 2.50~3.51 | 3186 (79) | 2.507(1.658–3.791) | <0.001 | 2.566(1.693–3.888) | <0.001 | 2.633 (1.725–4.019) | <0.001 |
| >3.51 | 3186 (108) | 3.459(2.325–5.148) | <0.001 | 3.604(2.416–5.375) | <0.001 | 4.231 (2.754–6.500) | <0.001 |
*a Model 1 adjusted for age, body mass index and sex
*b Model 2 adjusted for age, body mass index, sex, smoking, hypertension, diabetes mellitus, coronary artery disease, peripheral artery disease, stroke, levels of alanine aminotransferase, aspartate aminotransferase, uric acid, blood urea nitrogen, serum creatinine, triglyceride, total cholesterol, low-density lipoprotein cholesterol, fasting glucose and hemoglobin A1c, and use of angiotensin system inhibitors, beta-blockers, statins and metformin